Trane Technologies plc vs Zoetis Inc — how do they compare? Trane Technologies plc trades at $471.29 (market cap $105.17B), while Zoetis Inc trades at $75.31 (market cap $30.70B). The key difference: Trane Technologies plc is far larger — about 3.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| TT | ZTS | |
|---|---|---|
Market Cap | $105.17B | $30.70B |
Volume | 1,040,183 | 3,299,421 |
Sector | Industrials | Health |
52-Week High | $503.46 | $147.53 |
52-Week Low | $376.43 | $69.09 |
Enterprise Value | $108.47B | $38.27B |
Dividend Yield | 0.88% | 2.85% |
Typical Hold Time | — | 71 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $75.335, down 0.42% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported strong profitability with a 27.69% net income margin and 64.91% ROE for 2025, though Q1 2026 EPS missed expectations. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and industry-leading margins.
The outlook is cautiously optimistic, with a consensus price target of $87.33 implying 16% upside. Investment opportunities lie in Zoetis's robust fundamentals and market dominance, while risks include competitive pressures, weaker U.S. demand, and margin compression from promotions. The stock offers value at a P/E of 12.12, but investors should monitor Q3 2026 results for growth confirmation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Trane Technologies plc is a global climate solutions company that designs, manufactures, and services heating, ventilation, and air conditioning (HVAC) and transport refrigeration equipment under its Trane and Thermo King brands.
Read more on TT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →